medical_managment-key.png

CANCER

GENETIC CANCER RISK

Endocrine

High Risk

Other

High Risk

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

RISK FOR GENERAL POPULATION *

Pancreatic Neuroendocrine Tumors (PNET)

Lifetime risk

Up to 80%

<0.1%

Other MEN1-associated tumors and cancers

To age 80

Up to 100%

NA

MEN1

Associated Syndrome

Multiple Endocrine Neoplasia Type 1 (MEN Type

Core Cancer Risk(s)

Endocrine Cancer (Most common is tumors of the parathyroid gland)

Inheritance 

Autosomal Dominant 

Prevalence

Unknown

medical_managment-key.png

CANCER TYPE

PROCEDURE

AGE TO BEGIN

FREQUENCY

Pancreatic Neuroendocrine Tumors (PNET)

Clinical screening for symptoms

10 years

Annually

Biochemical screening

10 years

Annually

Abdominal MRI or multiphasic CT

10 years

Annually

Consider endoscopic ultrasound and/or functional imaging (i.e. PET/CT or PET/MRI)

Individualized

Individualized

Other MEN1-associated tumors and cancers

Multiple screenings recommended, including clinical screening for symptoms, biochemical screening, and imaging with MRI, CT, ultrasound and other methods

Some screenings are recommended to begin as early as age 5

Every 1 to 3 years